West Pharmaceutical Services Inc $ 300.09 0.41 (0.14%)
Volume:
516,433
Avg Vol (1m):
449,691
Market Cap $:
22.18 Bil
Enterprise Value $:
21.99 Bil
P/E (TTM):
72.66
P/B:
12.90
Current and historical daily P/E ratio for WST (West Pharmaceutical Services Inc) from 1990 to Jan 24 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. West Pharmaceutical Services stock (WST) PE ratio as of Jan 24 2021 is 72.66.
More Details
West Pharmaceutical Services PE Ratio (TTM) Chart
EMBED
West Pharmaceutical Services PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1255
- 1
- 2
- 3
- 4
- 5
- 6
- 14
West Pharmaceutical Services PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2021-01-24 | 72.7 | 2020-11-23 | 66.8 |
2021-01-22 | 72.7 | 2020-11-20 | 68.9 |
2021-01-21 | 72.6 | 2020-11-19 | 68.1 |
2021-01-20 | 73.9 | 2020-11-18 | 68.1 |
2021-01-19 | 72.7 | 2020-11-17 | 69.4 |
2021-01-18 | 72.5 | 2020-11-16 | 70.7 |
2021-01-15 | 72.5 | 2020-11-13 | 70.5 |
2021-01-14 | 72.3 | 2020-11-12 | 70.1 |
2021-01-13 | 72.2 | 2020-11-11 | 69.0 |
2021-01-12 | 72.3 | 2020-11-10 | 67.7 |
2021-01-11 | 73.2 | 2020-11-09 | 69.4 |
2021-01-08 | 74.5 | 2020-11-06 | 71.6 |
2021-01-07 | 73.6 | 2020-11-05 | 71.4 |
2021-01-06 | 71.2 | 2020-11-04 | 70.2 |
2021-01-05 | 70.5 | 2020-11-03 | 67.1 |
2021-01-04 | 69.2 | 2020-11-02 | 65.7 |
2021-01-01 | 68.6 | 2020-10-30 | 65.9 |
2020-12-31 | 68.6 | 2020-10-29 | 66.6 |
2020-12-30 | 67.8 | 2020-10-28 | 67.9 |
2020-12-29 | 67.4 | 2020-10-27 | 69.3 |
2020-12-28 | 67.2 | 2020-10-26 | 67.8 |
2020-12-25 | 68.5 | 2020-10-23 | 68.3 |
2020-12-24 | 68.5 | 2020-10-22 | 67.7 |
2020-12-23 | 68.1 | 2020-10-21 | 68.9 |
2020-12-22 | 68.5 | 2020-10-20 | 69.5 |
2020-12-21 | 66.9 | 2020-10-19 | 69.3 |
2020-12-18 | 67.2 | 2020-10-16 | 70.7 |
2020-12-17 | 66.2 | 2020-10-15 | 70.6 |
2020-12-16 | 64.8 | 2020-10-14 | 69.8 |
2020-12-15 | 64.7 | 2020-10-13 | 72.5 |
2020-12-14 | 64.2 | 2020-10-12 | 73.0 |
2020-12-11 | 63.9 | 2020-10-09 | 72.2 |
2020-12-10 | 64.6 | 2020-10-08 | 70.5 |
2020-12-09 | 63.2 | 2020-10-07 | 70.9 |
2020-12-08 | 64.7 | 2020-10-06 | 70.3 |
2020-12-07 | 64.9 | 2020-10-05 | 69.7 |
2020-12-04 | 65.8 | 2020-10-02 | 66.3 |
2020-12-03 | 65.9 | 2020-10-01 | 66.8 |
2020-12-02 | 66.7 | 2020-09-30 | 66.6 |
2020-12-01 | 65.9 | 2020-09-29 | 66.3 |
2020-11-30 | 66.6 | 2020-09-28 | 66.0 |
2020-11-27 | 67.3 | 2020-09-25 | 71.1 |
2020-11-26 | 65.2 | 2020-09-24 | 69.6 |
2020-11-25 | 65.2 | 2020-09-23 | 70.8 |
2020-11-24 | 64.8 | 2020-09-22 | 73.1 |
West Pharmaceutical Services PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
Compare
NYSE:COO
NYSE:TFX
NAS:HOLX
NYSE:STE
NAS:MASI
NYSE:VAR
NAS:XRAY
NYSE:RMD
NAS:RGEN
NYSE:HRC
NYSE:BDX
NAS:ISRG
XPAR:EL
NYSE:BAX
OCSE:COLO B
TSE:7741
XSWX:ALC
TSE:4543
XPAR:DIM
XTER:SRT
Address
530 Herman O. West Drive, Exton, PA, USA, 19341-0645
West Pharmaceutical Services is a Pennsylvania-based medical supplies company that operates as a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West develops, manufactures, and distributes elastomer-based supplies for the containment and administration of injectable drugs, including basic equipment such as syringes, stoppers, and plungers, along with somewhat more complicated devices including auto-injectors and other self-injection platforms. The company reports in two segments: proprietary products (75% of 2019 sales) and contract-manufactured products (25%). The firm generates 56% of its revenue from international markets and 44% from the United States.